Safety and immunogenicity of a heterologous boost with a recombinant vaccine, NVSI-06-07, in the inactivated vaccine recipients from UAE: a phase 2 randomised, double-blinded, controlled clinical trial
Nawal AlKaabi, Yun Kai Yang, Jing Zhang, Ke Xu, Yu Liang, Yun Kang, Ji Guo Su, Tian Yang, Salah Hussein, Mohamed Saif ElDein, Shuai Shao, Sen Sen Yang, Wenwen Lei, Xue Jun Gao, Zhiwei Jiang, Hui Wang, Meng Li, Hanadi Mekki Mekki, Walid Zaher, Sally Mahmoud, Xue Zhang, Chang Qu, Dan Ying Liu, Jing Zhang, Mengjie Yang, Islam ElTantawy, Peng Xiao, Zhao Nian Wang, Jin Liang Yin, Xiao Yan Mao, Jin Zhang, Ning Liu, Fu Jie Shen, Liang Qu, Yun Tao Zhang, Xiao Ming Yang, Guizhen Wu, Qi Ming Li
doi: https://doi.org/10.1101/2021.12.29.21268499
Nawal AlKaabi
1Sheikh Khalifa Medical City, SEHA, Abu Dhabi, United Arab Emirates
2College of Medicine and Health Sciences, Khalifa University, Abu Dhabi, United Arab Emirates
MBBSYun Kai Yang
3China National Biotec Group Company Limited, Beijing, China
Jing Zhang
6National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC), Beijing, China
BSKe Xu
6National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC), Beijing, China
PhDYu Liang
4The Sixth Laboratory, National Vaccine and Serum Institute (NVSI), Beijing, China
5National Engineering Center for New Vaccine Research, Beijing, China
MSYun Kang
4The Sixth Laboratory, National Vaccine and Serum Institute (NVSI), Beijing, China
5National Engineering Center for New Vaccine Research, Beijing, China
MSJi Guo Su
4The Sixth Laboratory, National Vaccine and Serum Institute (NVSI), Beijing, China
5National Engineering Center for New Vaccine Research, Beijing, China
PhDTian Yang
3China National Biotec Group Company Limited, Beijing, China
MSSalah Hussein
1Sheikh Khalifa Medical City, SEHA, Abu Dhabi, United Arab Emirates
MBBSMohamed Saif ElDein
1Sheikh Khalifa Medical City, SEHA, Abu Dhabi, United Arab Emirates
Shuai Shao
4The Sixth Laboratory, National Vaccine and Serum Institute (NVSI), Beijing, China
5National Engineering Center for New Vaccine Research, Beijing, China
MSSen Sen Yang
4The Sixth Laboratory, National Vaccine and Serum Institute (NVSI), Beijing, China
5National Engineering Center for New Vaccine Research, Beijing, China
MSWenwen Lei
6National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC), Beijing, China
PhDXue Jun Gao
7Lanzhou Institute of Biological Products Company Limited, Lanzhou, China
Zhiwei Jiang
8Beijing KeyTech Statistical Consulting Co.,Ltd, Beijing, China
Hui Wang
9Beijing Institute of Biological Products Company Limited, Beijing, China
Meng Li
3China National Biotec Group Company Limited, Beijing, China
Hanadi Mekki Mekki
10Union 71, United Arab Emirates
Walid Zaher
11G42 Healthcare, IROS (Insights Research Organization & Solutions), United Arab Emirates
PhDSally Mahmoud
11G42 Healthcare, IROS (Insights Research Organization & Solutions), United Arab Emirates
PhDXue Zhang
3China National Biotec Group Company Limited, Beijing, China
Chang Qu
3China National Biotec Group Company Limited, Beijing, China
Dan Ying Liu
3China National Biotec Group Company Limited, Beijing, China
Jing Zhang
4The Sixth Laboratory, National Vaccine and Serum Institute (NVSI), Beijing, China
5National Engineering Center for New Vaccine Research, Beijing, China
PhDMengjie Yang
6National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC), Beijing, China
MSIslam ElTantawy
11G42 Healthcare, IROS (Insights Research Organization & Solutions), United Arab Emirates
PhDPeng Xiao
11G42 Healthcare, IROS (Insights Research Organization & Solutions), United Arab Emirates
Zhao Nian Wang
3China National Biotec Group Company Limited, Beijing, China
Jin Liang Yin
3China National Biotec Group Company Limited, Beijing, China
Xiao Yan Mao
7Lanzhou Institute of Biological Products Company Limited, Lanzhou, China
Jin Zhang
8Beijing KeyTech Statistical Consulting Co.,Ltd, Beijing, China
Ning Liu
4The Sixth Laboratory, National Vaccine and Serum Institute (NVSI), Beijing, China
5National Engineering Center for New Vaccine Research, Beijing, China
MSFu Jie Shen
4The Sixth Laboratory, National Vaccine and Serum Institute (NVSI), Beijing, China
MSLiang Qu
3China National Biotec Group Company Limited, Beijing, China
Yun Tao Zhang
3China National Biotec Group Company Limited, Beijing, China
PhDXiao Ming Yang
3China National Biotec Group Company Limited, Beijing, China
MSGuizhen Wu
6National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC), Beijing, China
MSQi Ming Li
4The Sixth Laboratory, National Vaccine and Serum Institute (NVSI), Beijing, China
5National Engineering Center for New Vaccine Research, Beijing, China
PhD
Article usage
Posted January 04, 2022.
Safety and immunogenicity of a heterologous boost with a recombinant vaccine, NVSI-06-07, in the inactivated vaccine recipients from UAE: a phase 2 randomised, double-blinded, controlled clinical trial
Nawal AlKaabi, Yun Kai Yang, Jing Zhang, Ke Xu, Yu Liang, Yun Kang, Ji Guo Su, Tian Yang, Salah Hussein, Mohamed Saif ElDein, Shuai Shao, Sen Sen Yang, Wenwen Lei, Xue Jun Gao, Zhiwei Jiang, Hui Wang, Meng Li, Hanadi Mekki Mekki, Walid Zaher, Sally Mahmoud, Xue Zhang, Chang Qu, Dan Ying Liu, Jing Zhang, Mengjie Yang, Islam ElTantawy, Peng Xiao, Zhao Nian Wang, Jin Liang Yin, Xiao Yan Mao, Jin Zhang, Ning Liu, Fu Jie Shen, Liang Qu, Yun Tao Zhang, Xiao Ming Yang, Guizhen Wu, Qi Ming Li
medRxiv 2021.12.29.21268499; doi: https://doi.org/10.1101/2021.12.29.21268499
Safety and immunogenicity of a heterologous boost with a recombinant vaccine, NVSI-06-07, in the inactivated vaccine recipients from UAE: a phase 2 randomised, double-blinded, controlled clinical trial
Nawal AlKaabi, Yun Kai Yang, Jing Zhang, Ke Xu, Yu Liang, Yun Kang, Ji Guo Su, Tian Yang, Salah Hussein, Mohamed Saif ElDein, Shuai Shao, Sen Sen Yang, Wenwen Lei, Xue Jun Gao, Zhiwei Jiang, Hui Wang, Meng Li, Hanadi Mekki Mekki, Walid Zaher, Sally Mahmoud, Xue Zhang, Chang Qu, Dan Ying Liu, Jing Zhang, Mengjie Yang, Islam ElTantawy, Peng Xiao, Zhao Nian Wang, Jin Liang Yin, Xiao Yan Mao, Jin Zhang, Ning Liu, Fu Jie Shen, Liang Qu, Yun Tao Zhang, Xiao Ming Yang, Guizhen Wu, Qi Ming Li
medRxiv 2021.12.29.21268499; doi: https://doi.org/10.1101/2021.12.29.21268499
Subject Area
Subject Areas
- Addiction Medicine (386)
- Allergy and Immunology (701)
- Anesthesia (193)
- Cardiovascular Medicine (2859)
- Dermatology (244)
- Emergency Medicine (431)
- Epidemiology (12569)
- Forensic Medicine (10)
- Gastroenterology (807)
- Genetic and Genomic Medicine (4447)
- Geriatric Medicine (402)
- Health Economics (716)
- Health Informatics (2856)
- Health Policy (1050)
- Hematology (376)
- HIV/AIDS (893)
- Medical Education (415)
- Medical Ethics (114)
- Nephrology (464)
- Neurology (4201)
- Nursing (223)
- Nutrition (617)
- Oncology (2205)
- Ophthalmology (626)
- Orthopedics (254)
- Otolaryngology (319)
- Pain Medicine (269)
- Palliative Medicine (83)
- Pathology (488)
- Pediatrics (1172)
- Primary Care Research (483)
- Public and Global Health (6787)
- Radiology and Imaging (1494)
- Respiratory Medicine (902)
- Rheumatology (430)
- Sports Medicine (369)
- Surgery (473)
- Toxicology (57)
- Transplantation (202)
- Urology (174)